Treosulfan conditioning for stem cell transplant in Nijmegen breakage syndrome
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests a conditioning regimen using treosulfan before a stem cell transplant to treat Nijmegen breakage syndrome. It aims to make the transplant safer and more effective for patients with this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of Nijmegen breakage syndrome.
- You (if 14–21) or your legal guardian (if under 18) must sign a consent form.
- You must be healthy enough to undergo a stem cell transplant, with no other medical reasons that would make it unsafe.
- You must not have any other DNA repair deficiency syndromes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a low-dose chemotherapy regimen (treosulfan) combined with a drug called PTCy to prepare children with Nijmegen Breakage Syndrome for a stem cell transplant. The goal is to reduce side effects while helping the donor cells take hold safely.
This study watches how the chemotherapy drug Treosulfan works in children getting a stem cell transplant. The goal is to make sure the dose is just right for each child.
This trial tests whether the chemotherapy medicine treosulfan (Trecondi® Ideogen) works well and is safe for people with myeloma who are moving on to high-dose chemotherapy plus their own stem cell transplant. It may help strengthen the transplant “conditioning” treatment before the transplant.
This Phase 2 study tests a specific chemotherapy combination (treosulfan, fludarabine, and thiotepa) before an unrelated or matched donor stem cell transplant. It may help people with certain non-cancer blood and immune disorders by trying to reset the immune system using donor stem cells.
This trial tests a gentler chemotherapy regimen (fludarabine and treosulfan) before a stem cell transplant from a half-matched donor. It aims to make the transplant safer and more effective for older or frailer patients with acute myeloid leukemia.
This trial tests a conditioning regimen that is adjusted by age for people with low- or intermediate-risk myelodysplastic syndromes (MDS) who are receiving a half-matched (haploidentical) stem cell transplant from a family donor. The goal is to see if an age-stratified approach can improve outcomes.
Hear when a new HSCT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.